C188
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561535

CAS#: 823828-18-8

Description: C188 is a STAT3 inhibitor. C188 is a cell-permeable naphthol compound that inhibits IL-6-stimulated STAT3 Tyr705 phosphorylation and nuclear translocation in HepG2 cells by targeting STAT3 SH2 domain peptide-binding pocket, while exhibiting little effect against IFN-γ-stimulated HepG2 cellular STAT1 phosphorylation.


Price and Availability

Size
Price

10mg
USD 260
Size
Price

Size
Price

C188, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 561535
Name: C188
CAS#: 823828-18-8
Chemical Formula: C19H15NO7S2
Exact Mass: 433.029
Molecular Weight: 433.44
Elemental Analysis: C, 52.65; H, 3.49; N, 3.23; O, 25.84; S, 14.79


Synonym: C188; C-188; C 188; STAT3-IN-C188; Cpd188; Cpd-188; Cpd 188;

IUPAC/Chemical Name: 4-(3-Carboxymethylsulfanyl-4-hydroxy-naphthalen-1-ylsulfamoyl)-benzoic acid

InChi Key: CIERPRDYPKVDJO-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H15NO7S2/c21-17(22)10-28-16-9-15(13-3-1-2-4-14(13)18(16)23)20-29(26,27)12-7-5-11(6-8-12)19(24)25/h1-9,20,23H,10H2,(H,21,22)(H,24,25)

SMILES Code: O=C(O)C1=CC=C(S(=O)(NC2=C3C=CC=CC3=C(O)C(SCC(O)=O)=C2)=O)C=C1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Pedroza M, To S, Assassi S, Wu M, Tweardy D, Agarwal SK. Role of STAT3 in skin fibrosis and transforming growth factor beta signalling. Rheumatology (Oxford). 2017 Sep 23. doi: 10.1093/rheumatology/kex347. [Epub ahead of print] PubMed PMID: 29029263.

2: Akinfenwa PY, Bond WS, Ildefonso CJ, Hurwitz MY, Hurwitz RL. Versican G1 domain enhances adenoviral-mediated transgene expression and can be modulated by inhibitors of the Janus kinase (JAK)/STAT and Src family kinase pathways. J Biol Chem. 2017 Sep 1;292(35):14381-14390. doi: 10.1074/jbc.M116.773549. Epub 2017 Jul 6. PubMed PMID: 28684419; PubMed Central PMCID: PMC5582833.

3: Jung KH, Yoo W, Stevenson HL, Deshpande D, Shen H, Gagea M, Yoo SY, Wang J, Eckols TK, Bharadwaj U, Tweardy DJ, Beretta L. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice. Clin Cancer Res. 2017 Sep 15;23(18):5537-5546. doi: 10.1158/1078-0432.CCR-16-2253. Epub 2017 May 22. PubMed PMID: 28533225.